Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · Lancet Rheumatol · 2026-09-29

In a post hoc analysis of a phase 2a trial of 98 adults with moderate-to-severe rheumatoid arthritis, the PD-1 agonist peresolimab (700 or 300 mg) lowered PD-1-high CD4 T cells by 52–57% from baseline and neutrophils by >10%, and down-modulated IL-6 and other cytokine pathways.

Secondary analysisn = 98
Benschop et al. Cellular and proteomic changes following administration of peresolimab in patients with rheumatoid arthritis: a post-hoc analysis of a randomised phase 2a trial
Rheumatology · Ann Rheum Dis · 2026-09-23

Post hoc analysis of 649 PEXIVAS participants with severe ANCA-associated vasculitis in remission: a model using sex, induction agent, ANCA subtype, organ involvement and eGFR predicted 2-year first relapse (100 relapses) with C-statistic 0.709; needs external validation.

Secondary analysisn = 649
Junek et al. Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial
Rheumatology · Ann Rheum Dis · 2026-08-22

In a phase 2 trial of 56 adults with SLE and objective neuropsychological dysfunction, 12 weeks of memantine vs placebo gave a greater median RBANS total score gain (+8 vs +5; P=.032; 43 analysed). Self-reported improvement did not differ significantly (61% vs 36%).

RCTn = 56
Rhoads et al. Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.